Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
Palabras clave
Abstracto
Descripción
Fetal complete (3°) atrioventricular block (AVB), identified in the 2nd trimester in an otherwise normally developing heart, is almost universally associated with maternal anti-Ro autoantibodies, which transcytose the placenta via the trophoblastic IgG receptor, FcγRn. The burden of 3° AVB is considerable: perinatal mortality of 18% exceeds that for all non-cardiac congenital anomalies combined, and almost all survivors require lifelong cardiac pacing with its associated complications. It has been speculated that full expression of conduction disease occurs by sequential fetal progression from normal rhythm (NR) to 1° AVB [prolonged AV interval assessed by echocardiogram (echo)], to 2° AVB (irregular cardiac rhythm or bradycardia), culminating in 3° AVB. Fetal heart rate and rhythm monitoring (FHRM) suggests a time interval of ~12 hours for the transition from NR to 3° AVB, albeit the culprit biologic processes (inflammation leading to fibrosis) likely initiate prior to clinical detection. Anecdotal evidence suggests this transition period, marked by an irregular rhythm and/or bradycardia, may be the only window of opportunity for anti-inflammatory treatment to restore NR.
A barrier to preventing progression to 3° AVB is the absence of a technique to accurately surveil for the precipitate transition from NR to 3° AVB. Surveillance limited to weekly echos (current standard of care) may be too infrequent to detect this transition period when treatment is most likely to be effective. We have now obviated this obstacle and shown that ambulatory FHRM by the mother at home with confirmation of abnormal findings by echo is not only feasible but may afford rapid treatment restoring NR. Combining results from studies comprising 275 anti-Ro+ pregnancies, 87% completed monitoring with a false positive rate of 5%. In 4 cases of 2° AVB identified by FHRM and treated <12h, AVB reversed. Remarkably, no cases of 2° or 3° AVB were missed, suggesting mothers can recognize abnormal FHRM, reducing or precluding the need for weekly echos.
The proposed project combines the expertise of fetal cardiologist Bettina F. Cuneo, MD, initiator and PI of the FHRM program, and rheumatologist Jill P. Buyon, MD, founder/director of the largest extant registry of anti-Ro-mediated AVB, whose research on the pathogenesis supports a fetal inflammatory component associated with high-titer antibodies. Participants will be referred from 35 sites in 3 sequential Steps: 1) Screening for high titer anti-Ro60 or Ro52 centrally in Dr. Buyon's lab; 2) Surveillance by FHRM 3x daily and weekly echo; 3) Treatment of 2° AVB identified by FHRM confirmed by echo. Feasibility of FHRM supported by weekly echo of high-autoantibody-titer mothers will be leveraged to address the efficacy of expeditious (<12 h after detection) treatment of 2° AVB as well as the incidence/outcome of AV interval prolongation and extra-nodal disease.
fechas
| Verificado por última vez: | 06/30/2020 |
| Primero enviado: | 07/13/2020 |
| Inscripción estimada enviada: | 07/13/2020 |
| Publicado por primera vez: | 07/15/2020 |
| Última actualización enviada: | 07/13/2020 |
| Última actualización publicada: | 07/15/2020 |
| Fecha de inicio real del estudio: | 07/31/2020 |
| Fecha estimada de finalización primaria: | 07/31/2025 |
| Fecha estimada de finalización del estudio: | 12/31/2025 |
Condición o enfermedad
Intervención / tratamiento
Drug: Mothers with Fetuses Who Have 2° AVB or AV interval > 170ms
Drug: Mothers with Fetuses Who Have 2° AVB or AV interval > 170ms
Fase
Grupos de brazos
| Brazo | Intervención / tratamiento |
|---|---|
| Experimental: Mothers with Fetuses Who Have 2° AVB or AV interval > 170ms | Drug: Mothers with Fetuses Who Have 2° AVB or AV interval > 170ms In mother in whom 2° AVB or AV interval >170 ms has been diagnosed in the fetus:
Dexamethasone 8 mg po/day for 10 days. Then dexamethasone 4 mg po/ day through 28 weeks 6 days gestational age (GA); then 3 mg/day from 29 wks 0 days to 29 wks 6 days GA; then 2 mg/day until delivery |
Criterio de elegibilidad
| Edades elegibles para estudiar | 18 Years A 18 Years |
| Sexos elegibles para estudiar | Female |
| Acepta voluntarios saludables | si |
| Criterios | Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Be <18 weeks pregnant at the time of enrollment 4. Titer of anti-Ro 52 or 60 antibodies ≥1,000 EU 5. Any positive titer of anti-Ro if a history of a previously affected child 6. Ability to take oral medication and be willing to adhere to the dexamethasone and IVIG protocols. 7. Ability to perform Doppler fetal heart rate and rhythm monitoring in the ambulatory setting, 8. Ability to send an audiotext message by cell phone therefore the participant will be informed that they need a phone with texting capabilities. Located within 6 hours drive of the participating pediatric cardiology site 9. Be ≥18 years of age Exclusion Criteria: 1. Multi-fetal pregnancy 2. Known allergic reactions to components of IVIG, or dexamethasone or maternal IgA deficiency 3. Fetal conduction system disease already present in the current pregnancy 4. Any women who in the opinion of the investigator cannot understand the consent form or be able to perform thrice daily home monitoring or recognize an abnormal fetal heart rate or rhythm 5. Women prisoners 6. Treatment with >20 mg/prednisone q day or with any dose of fluorinated steroids at enrollment |
Salir
Medidas de resultado primarias
1. Percentage of 2° AVB subjects with NR (1:1 AV conduction) at birth [up to 25 weeks post-enrollment]
Medidas de resultado secundarias
1. Percentage of 2° AVB subjects who maintain NR at age 1 year. [1 year post-birth]
2. Percentage of AV interval > 170 msec subjects with NR at birth [At birth]
3. Incidences of isolated extra-nodal cardiac disease [up to 1 year post-birth]
